Phapros Expands Men's Health Portfolio with New Erectile Dysfunction Treatment

Strategic Product Launch at InaSAU 2025

PT Phapros Tbk (PEHA), an Indonesian pharmaceutical company, has launched a new erectile dysfunction (DE) therapy product at The 4th InaSAU Meeting 2025 held in Lombok on December 19-20, 2025. The new product is an oral dissolving film (ODF) formulation based on tadalafil, designed to enhance patient convenience and compliance.

Addressing Growing Men's Health Market

The launch is part of Phapros' strategic expansion into the specialty therapy segment, particularly in men's health. The company sees significant potential in Indonesia's erectile dysfunction treatment market due to increasing health awareness among men. Acting President Director Ida Rahmi Kurniasih emphasized that this innovation aligns with the company's commitment to developing patient-centric healthcare solutions that follow current clinical practices.

Product Innovation and Market Potential

The new ODF product represents a significant innovation in erectile dysfunction treatment. By using tadalafil in an oral dissolving film format, Phapros has created a more convenient and discreet treatment option. This product addresses the growing demand for effective and user-friendly men's health solutions in Indonesia's evolving pharmaceutical market.